Coya rises as Alzheimer's drug meets safety and shows immune response in trial

Coya Therapeutics

29/10/2024 11:47

** Shares of drug developer Coya Therapeutics  COYA.O  rise
~7.8% to $10.98 premarket
    ** Co says its experimental Alzheimer's drug was safe and
increased levels of a type of immune cells in patients with
Alzheimer's disease during a small, mid-stage trial
    ** The antibody drug COYA 301, part of the IL-2 treatment
class, aims to enhance the function of regulatory T cells, which
suppress immune responses
    ** Says, once-a-month treatment with the drug showed a
slight improvement in cognitive function and also improved
levels of the disease-related protein beta-amyloid in the brain
and spinal fluid
    ** Up to last close, stock up 37.5% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))